Loading
A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. is a phase 2 interventional study registered as NCT06514534 by Novartis Pharmaceuticals, with 20 participants planned, started 2025-02-18 and due to reach its primary completion in 2029-02-17. Interventions recorded: ABL001/Asciminib.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML), Novartis and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML), Novartis and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML), Novartis and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML), Novartis and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.